 |
인쇄하기
취소
|
Chong Kun Dang to launch anti-clotting agent
Chong Kun Dang Pharmaceutical is considering launching its chemical modified Prigrel tablet (clopidogrel reginate) in the domestic thrombolytic market dominated by Sanofi-Aventis’s Plavix (clopidogrel bisulfate).
Plavix’s last year sales amounted to 110 billion won, ranking a top position in the sales of top brand items.
“Prigrel’s efficacy and safety has been firmly established through p...
Plavix’s last year sales amounted to 110 billion won, ranking a top position in the sales of top brand items.
“Prigrel’s efficacy and safety has been firmly established through p...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.